9-cyclopentyl-8-hydroxyadenine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-cyclopentyl-8-hydroxyadenine
• 英文别名: 6-amino-9-cyclopentyl-7H-purin-8-one
• 化学式: C₁₀H₁₃N₅O
• 分子量: 219.246
• InChiKey: GVHPUWNLUBNXJJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  84.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [4-[[(2-methoxybenzoyl)amino]methyl]phenyl]boronic acid 、 9-cyclopentyl-8-hydroxyadenine 在 吡啶 、 copper diacetate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(4-(6-amino-9-cyclopentyl-8-oxo-8,9-dihydro-7H-purin-7-yl)benzyl)-2-methoxybenzamide
  参考文献：
  名称：

  [EN] COMPOUNDS USEFUL AS KINASE INHIBITORS
  [FR] COMPOSÉS UTILES EN TANT QU'INHIBITEURS DE KINASE

  摘要：

  提供了某些BTK抑制剂，其药物组成物以及使用方法。

  公开号：

  WO2021180107A1
• 作为产物：
  描述：

  8-溴腺嘌呤 在 甲酸 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 72.25h， 生成 9-cyclopentyl-8-hydroxyadenine
  参考文献：
  名称：

  Synthetic Strategies to 9-Substituted 8-Oxoadenines

  摘要：

  Three synthetic routes to 9-substituted 8-oxoadenines have been studied: bromination of adenine followed by N-9-alkylation/arylation and finally hydrolysis; bromination of adenine, hydrolysis, and N-functionalization as the last step; and N-9-alkylation of adenine, halogenation, and finally hydrolysis. As long as the N-9-functional group is compatible with conditions required for introduction of the halogen, the latter strategy was the most efficient. Also, a strategy starting from 5-amino-4,6-dichloropyrimidine was found to be a very good alternative for synthesis of 9-substituted 8-oxoadenines. Supplemental materials are available for this article. Go to the publisher's online edition of Synthetic Communications (R) to view the free supplemental file.

  DOI：

  10.1080/00397911.2011.642051

文献信息

• Type 2 helper T cell-selective immune response suppressors
  申请人：Japan Energy Corporation

  公开号：US06376501B1

  公开（公告）日：2002-04-23

  The present invention relates to a type 2 helper T cell-selective immune response inhibitor, an immune response regulator and an anti-allergic agent, individually comprising, as an active ingredient, a purine derivative represented by General Formula (I): wherein R2 is hydrogen or a hydrocarbon group in which —CH2— not directly bound to the purine skeleton may be substituted by CO, SO2, O or S, and C—H not directly bound to the purine skeleton may be substituted by N, C-halogen or C—CN; R6 is hydroxyl, amino or amino which is mono- or di-substituted by a hydrocarbon group(s); R8 is hydroxyl, mercapto, acyloxy or hydrocarbon group-substituting oxycarbonyloxy; and R9 is a hydrocarbon group in which —CH2— not directly bound to the purine skeleton may be substituted by CO, SO2, O or S, and C—H not directly bound to the purine skeleton may be substituted by N, C-halogen or C—CN; or its tautomer or a salt of the purine derivative or the tautomer.

  本发明涉及一种选择性抑制T细胞辅助型2型免疫应答的免疫应答调节剂、免疫调节剂和抗过敏剂，分别包括一种以通式(I)表示的嘌呤衍生物作为活性成分：其中R2是氢或烃基，在其中—CH2—不直接与嘌呤骨架结合的部分可能被CO、SO2、O或S取代，而未直接与嘌呤骨架结合的部分可能被N、C-卤或C—CN取代；R6是羟基、氨基或被一个或两个烃基取代的氨基；R8是羟基、巯基、酰氧基或烃基取代的氧羰氧基；以及R9是烃基，在其中—CH2—不直接与嘌呤骨架结合的部分可能被CO、SO2、O或S取代，而未直接与嘌呤骨架结合的部分可能被N、C-卤或C—CN取代；或其互变异构体或嘌呤衍生物或其互变异构体的盐。
• TYPE 2 HELPER T CELL-SELECTIVE IMMUNE RESPONSE SUPPRESSORS
  申请人：Japan Energy Corporation

  公开号：EP1043021A1

  公开（公告）日：2000-10-11

  The present invention relates to a type 2 helper T cell-selective immune response inhibitor, an immune response regulator and an anti-allergic agent, individually comprising, as an active ingredient, a purine derivative represented by General Formula (I):    wherein R2 is hydrogen or a hydrocarbon group in which -CH2- not directly bound to the purine skeleton may be substituted by CO, SO2, O or S, and C-H not directly bound to the purine skeleton may be substituted by N, C-halogen or C-CN; R6 is hydroxyl, amino or amino which is mono- or di-substituted by a hydrocarbon group(s); R8 is hydroxyl, mercapto, acyloxy or hydrocarbon group-substituting oxycarbonyloxy; and R9 is a hydrocarbon group in which -CH2- not directly bound to the purine skeleton may be substituted by CO, SO2, O or S, and C-H not directly bound to the purine skeleton may be substituted by N, C-halogen or C-CN; or its tautomer or a salt of the purine derivative or the tautomer.

  本发明涉及一种 2 型辅助性 T 细胞选择性免疫应答抑制剂、免疫应答调节剂和抗过敏剂，其活性成分分别包括通式 (I) 所代表的嘌呤衍生物： 其中 R2 是氢或烃基，其中与嘌呤骨架不直接结合的-CH2-可被 CO、SO2、O 或 S 取代，与嘌呤骨架不直接结合的 C-H 可被 N、C-卤素或 C-CN 取代； R6 是羟基、氨基或被烃基单取代或二取代的氨基； R8 是羟基、巯基、酰氧基或被烃基取代的氧羰氧基；以及 R9 是烃基，其中与嘌呤骨架不直接结合的-CH2-可被 CO、SO2、O 或 S 取代，与嘌呤骨架不直接结合的 C-H 可被 N、C-卤素或 C-CN 取代； 或其同系物，或该嘌呤衍生物或其同系物的盐。
• US6028076
  申请人：——

  公开号：——

  公开（公告）日：——
• PURINE DERIVATIVES FOR THE TREATMENT OF ALLERGIC DISEASES AND SYSTEMIC LUPUS ERYTHEMATOSUS
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1043021B1

  公开（公告）日：2006-05-03
• NOVEL PURINE DERIVATIVES
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：EP0882727B1

  公开（公告）日：2004-12-01